MIOTEPA 100 – Thiotepa for Injection USP 100 mg

Description

MIOTEPA 100

• Thiotepa is indicated to reduce the risk of graft rejection when used in conjunction with high-dose Busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (Hscn for pediatric patients with class3 beta-thalassemia.
• Thiotepa is indicated for the treatment of adenocarcinoma of the breast or ovary.
• Thiotepa is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities.
• Thiotepa is indicated for treatment of superficial papillary carcinoma of the urinary bladder.